68Ga-HSA PET/CT Imaging for Protein-losing Enteropathy

Launched by PEKING UNIVERSITY CANCER HOSPITAL & INSTITUTE · Dec 2, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new imaging technique called 68Ga-HSA PET/CT to help doctors better diagnose a rare condition known as Protein-Losing Enteropathy (PLE), which can happen in some cancer patients. PLE causes the body to lose protein through the intestines, leading to serious health issues. The goal of the study is to create a more advanced imaging tool that provides clearer images of the intestines, allowing doctors to pinpoint where the leakage occurs and understand the underlying problems. This could greatly enhance the way PLE is diagnosed and treated.

To participate in the trial, patients should be between the ages of 65 and 93 and have certain digestive system tumors, along with symptoms like low protein levels in their blood. They should also have measurable lesions visible on scans and a predicted survival time of more than three months. However, individuals with severe liver or kidney issues, pregnant or nursing women, and those who may have allergies to the study drug are not eligible. Participants can expect to undergo PET/CT imaging procedures, which will help researchers gather important information about PLE and improve future treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with digestive system tumors;
• • 2. Presence of hypoproteinemia or clinical manifestations of hypoplasma protein;
• • 3. Serum albumin \<30 g/L, AAT\>80 ml/d;
• • 4. Measurable lesions in imaging;
• • 5. Predicted survival greater than 3 months;
• Exclusion Criteria:
• • 1. Severe hepatic or renal dysfunction;
• • 2. Pregnant or nursing;
• • 3. Known allergy to the investigational drug or its excipients in study;
• • 4. Unable to comply with the PET/CT imaging procedures;
• • 5. Claustrophobia or other psychiatric disorders;
• • 6. Other conditions deemed unsuitable for participation in the trial;